Duke University School of Medicine, Division of Infectious Diseases, Durham, North Carolina, USA
Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina, USA.
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02337-18. Print 2019 Mar.
Treatment options for drug-resistant cytomegalovirus (CMV) are limited. Letermovir is a novel antiviral recently approved for CMV prophylaxis following hematopoietic cell transplantation, but its efficacy in other settings is unknown. We recently used letermovir for salvage treatment in four solid organ transplant recipients with ganciclovir-resistant CMV retinitis. All patients improved clinically without known adverse drug events. However, three patients failed to maintain virologic suppression, including two patients who developed genotypically confirmed resistance to letermovir while on therapy.
治疗药物耐药性巨细胞病毒 (CMV) 的方法有限。来特莫韦是一种新型抗病毒药物，最近被批准用于造血细胞移植后 CMV 的预防，但它在其他情况下的疗效尚不清楚。我们最近使用来特莫韦对 4 例更昔洛韦耐药的 CMV 视网膜炎的实体器官移植受者进行了挽救性治疗。所有患者的临床症状均有改善，无已知的药物不良反应。然而，有 3 名患者未能维持病毒学抑制，其中 2 名患者在治疗过程中发生了来特莫韦基因型确认耐药。
